CF and Airways Microbiology Research Group, Queens University Belfast, Belfast, UK.
Expert Rev Respir Med. 2013 Aug;7(4):385-96. doi: 10.1586/17476348.2013.814411.
Cystic fibrosis (CF) is characterised by chronic polymicrobial airway infection and inflammation, which is the major cause of morbidity and mortality. Aggressive use of antimicrobials has been fundamental in increasing the life expectancy of CF patients in recent years. However, enhanced culture and non-culture based detection methods have identified bacteria in the CF lung not previously isolated from CF patients by routine diagnostic microbiology Coupled with increasing antimicrobial resistance, the future of antimicrobial therapy in CF respiratory infection remains challenging. New strategies are needed to address these problems and ensure improvements in life expectancy are maintained. Potential future strategies include the use of new antimicrobial agents and formulations currently in clinical trials, alternative methods of selecting appropriate therapeutic regimens, determination of the pathogenicity of species newly associated with CF and the development of new antimicrobials and adjuvants for use in clinical practice.
囊性纤维化（CF）的特征是慢性多微生物气道感染和炎症，这是发病率和死亡率的主要原因。近年来，积极使用抗生素在提高 CF 患者的预期寿命方面发挥了重要作用。然而，增强的培养和非培养为基础的检测方法已经确定了 CF 肺部中的细菌，这些细菌以前并未通过常规诊断微生物学从 CF 患者中分离出来。再加上抗菌药物耐药性的增加，CF 呼吸道感染的抗菌治疗的未来仍然具有挑战性。需要新的策略来解决这些问题，并确保维持预期寿命的提高。潜在的未来策略包括使用目前正在临床试验中的新的抗菌药物和制剂，选择适当治疗方案的替代方法，确定与 CF 新相关的物种的致病性，以及开发新的抗菌药物和佐剂用于临床实践。
